Mesa Laboratories, Inc. MLAB R2K
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 84.3.
- Earnings shrank at -68.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Technology).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MLAB Mesa Laboratories, Inc. R2K | 102.02 | 84.31 | $563.64M | 0.63% | 6.62% | 3.88% | 9.34% | -68.50% |
| 2 | NVDA NVIDIA Corporation NDXSPXAI | 211.14 | 32.38 | $5.11T | 0.47% | 81.14% | 114.29% | 100.05% | 201.80% |
| 3 | AAPL Apple Inc. NDXSPX | 312.06 | 37.73 | $4.58T | 0.35% | 68.72% | 141.47% | 1.81% | 3.92% |
| 4 | MSFT Microsoft Corporation NDXSPXAI | 450.24 | 26.82 | $3.34T | 0.81% | 26.37% | 34.01% | 12.42% | 11.87% |
| 5 | TSM Taiwan Semiconductor Manufacturing Company Limited AI | 418.45 | 35.86 | $2.17T | 0.91% | 32.04% | 36.21% | 18.94% | 19.57% |
| 6 | MU Micron Technology, Inc. NDXSPXAI | 971.00 | 45.87 | $1.10T | 0.06% | 14.20% | 39.82% | 6.71% | -0.57% |
| 7 | AMD Advanced Micro Devices, Inc. NDXSPXAI | 516.10 | 172.61 | $841.55B | - | 6.33% | 8.06% | 13.64% | 48.64% |
| 8 | ORCL Oracle Corporation SPXAI | 225.78 | 40.46 | $649.35B | 0.89% | 13.07% | 57.57% | 10.59% | 22.81% |
| 9 | ASML ASML Holding N.V. NDXAI | 1,612.76 | 53.76 | $621.59B | 0.54% | 43.81% | 52.24% | 15.55% | 19.55% |
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 25.14M | 24.86M | 26.68M | - | 26.29M | 25.54M | 31.66M | - | 29.94M | 31.86M | 34.17M | - | 34.92M | 35.84M | 54.70M | 50.45M | 58.75M | 54.29M | 50.65M | 53.16M | 53.47M | 58.17M | 57.83M | 62.84M | 62.13M | 59.54M | 60.74M | 65.13M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.09M | 23.72M | 22.60M | 23.41M | 23.33M | - |
| Gross Profit | 13.07M | 12.21M | 15.00M | 12.01M | 13.72M | 13.54M | 13.96M | 12.67M | 13.23M | 12.68M | 16.03M | 15.09M | 14.58M | 15.63M | 15.61M | 16.20M | 15.59M | 14.80M | 18.77M | 20.34M | 21.29M | 20.65M | 24.74M | 22.21M | 23.14M | 28.63M | 31.34M | 36.39M | 32.77M | 31.18M | 32.11M | 33.40M | 37.25M | 35.45M | 39.75M | 38.41M | 36.94M | 37.33M | 41.80M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.98M | 36.94M | 33.88M | 32.61M | 33.82M | - |
| Operating Income | 3.01M | 3.83M | - | 2.58M | 4.01M | 4.39M | - | 1.98M | 3.65M | -10.09M | - | 4.76M | 1.14M | 1.32M | - | 5.39M | 4.69M | -3.25M | - | 3.57M | 4.47M | 22.00K | - | 3.12M | 4.20M | -2.51M | -4.59M | 4.00M | 3.40M | -664.00K | -60.00K | -67.00K | 5.58M | 3.51M | 5.78M | 1.47M | 3.06M | 4.72M | 7.97M | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.12M | 10.48M | 15.17M | 10.71M | 13.35M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.84M | 2.52M | 2.20M | 2.86M | 3.04M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.22M | 461.00K | 7.01M | 2.00M | 4.60M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -541.00K | 7.58M | 2.27M | -477.00K | 966.00K | - |
| Net Income | - | - | - | - | - | - | - | 1.52M | 2.35M | - | - | 4.23M | 994.00K | - | - | - | - | - | - | 1.22M | 2.68M | -4.54M | - | 2.00M | 3.72M | -2.06M | -1.44M | 1.31M | 451.00K | -549.00K | -1.23M | 2.12M | 3.39M | 3.43M | -1.68M | -7.11M | 4.74M | 2.48M | 3.63M | - |
| Diluted EPS | 0.48 | 0.69 | - | 0.51 | 0.62 | 0.84 | - | 0.39 | 0.60 | -2.93 | 1.08 | 1.06 | 0.25 | 0.21 | 0.34 | 1.14 | 0.73 | -1.03 | -0.37 | 0.26 | 0.51 | -0.89 | 0.74 | 0.38 | 0.70 | -0.39 | -0.27 | 0.24 | 0.08 | -0.10 | -0.23 | 0.39 | 0.62 | 0.63 | - | -1.31 | 0.85 | 0.45 | 0.65 | -0.75 |
| R&D Expense | 991.00K | 975.00K | - | 1.03M | 1.04M | 861.00K | - | 1.15M | 885.00K | 752.00K | - | 837.00K | 842.00K | 860.00K | - | 1.02M | 915.00K | 2.11M | - | 2.60M | 2.41M | 2.71M | - | 2.81M | 2.61M | 5.16M | 5.70M | 4.99M | 4.80M | 4.81M | 4.99M | 4.29M | 4.74M | 4.63M | 5.05M | - | 4.98M | 5.05M | 5.03M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 93.67M | 96.18M | 103.14M | 117.69M | 133.94M | 184.34M | 219.08M | 216.19M | 240.98M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 75.25M | 85.39M | 82.94M | 90.11M |
| Gross Profit | 19.57M | 23.51M | 28.86M | 31.69M | 43.39M | 51.41M | 53.24M | 54.62M | 60.92M | 65.36M | 87.01M | 109.09M | 133.69M | 133.25M | 150.87M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 104.39M | 130.37M | 130.79M | 134.53M |
| Operating Income | 9.86M | 12.48M | 13.10M | 11.79M | 15.86M | 16.32M | 16.31M | 2.18M | 9.78M | 7.92M | 12.36M | 4.70M | 3.32M | 2.46M | 16.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | 32.53M | 37.52M | -238.38M | 42.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 3.88M | 4.77M | 5.70M | 11.86M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | 3.57M | -389.00K | -275.65M | 5.96M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 1.70M | -1.32M | -21.40M | 7.93M |
| Net Income | - | - | - | - | - | - | - | - | - | - | 3.27M | 1.87M | 930.00K | -254.25M | -1.97M |
| Diluted EPS | 1.86 | 2.29 | 2.35 | 2.49 | 2.63 | 2.97 | 2.91 | -0.79 | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | -47.20 | -0.36 |
| R&D Expense | 1.44M | 1.36M | 2.01M | 2.32M | 3.29M | 3.97M | 4.16M | 3.54M | 3.51M | 6.36M | 10.39M | 15.77M | 20.49M | 19.30M | 19.52M |
Compounded Sales Growth
| 5 Years: | 9.34% |
| 1 Year: | 2.60% |
Compounded Profit Growth
| 5 Years: | -68.50% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +2.16% |
| 6 Months: | +26.34% |
| 3 Months: | +5.81% |
| 1 Month: | +6.70% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.56M | 50.70M | 65.92M | 97.53M | 117.32M | 160.75M | 171.73M | 164.10M | 156.77M | 409.11M | 601.48M | 707.37M | 661.83M | 446.80M | 433.35M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 124.32M | 118.97M | 109.35M | 102.69M |
| Cash & Equivalents | 10.47M | 3.55M | 7.19M | 4.01M | 5.58M | 2.03M | 5.70M | 5.82M | 5.47M | 10.19M | 81.38M | 263.87M | 49.35M | 32.91M | 28.21M | 27.32M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 24.61M | 34.64M | 32.67M | 25.36M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 41.22M | 42.55M | 39.05M | 41.97M |
| Total Liabilities | - | 14.14M | 6.78M | 13.17M | 33.20M | 43.84M | 76.07M | 73.91M | 64.74M | 45.46M | 189.09M | 195.25M | 313.57M | 268.35M | 301.40M | 273.52M |
| Current Liabilities | - | 9.93M | 4.26M | 4.66M | 10.21M | 14.66M | 23.97M | 16.57M | 17.29M | 23.66M | 26.01M | 32.58M | 48.05M | 43.36M | 44.31M | 163.96M |
| Long Term Debt | - | 1.50M | - | 4.00M | 16.50M | 23.25M | 42.25M | 53.67M | 44.63M | 20.61M | - | - | 218.37M | 183.27M | 221.70M | 76.90M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 221.13M | 186.14M | 224.68M | 181.47M |
| Total Equity | 31.20M | 36.42M | 43.91M | 52.75M | 64.33M | 73.48M | 84.68M | 97.82M | 99.36M | 111.31M | 220.01M | 406.23M | 393.80M | 393.48M | 145.39M | 159.83M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 5.27M | 5.37M | 5.39M | 5.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | 16.90M | 17.30M | 25.72M | 30.55M | 26.99M | 37.07M | 39.22M | 27.98M | 44.13M | 46.81M |
| Investing Cash Flow | - | - | - | - | - | -31.84M | -18.41M | -17.18M | -3.88M | -185.59M | -1.99M | -305.23M | -9.49M | -81.31M | -4.50M |
| Financing Cash Flow | - | - | - | - | - | 18.62M | 1.15M | -9.02M | -21.67M | 231.28M | 146.23M | 52.58M | -33.33M | 32.84M | -44.51M |
| Capital Expenditure | - | - | - | - | - | - | - | -2.80M | -1.26M | -1.50M | -1.99M | -4.43M | -4.54M | -2.57M | -4.50M |
| Free Cash Flow | - | - | - | - | - | - | - | 22.92M | 29.29M | 25.49M | 35.08M | 34.79M | 23.44M | 41.57M | 42.31M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -213.43M | -14.84M | -4.34M | -2.20M |
| Share Buybacks | 105.00K | 597.00K | 102.00K | 22.00K | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | 1.99M | 2.18M | 2.30M | 2.35M | 2.41M | 2.46M | 2.72M | 3.17M | 3.34M | 3.41M | 3.45M | 3.47M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | 56.8% | 56.8% | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% |
| Operating Margin % | - | - | - | - | - | - | 17.4% | 2.3% | 9.5% | 6.7% | 9.2% | 2.6% | 1.5% | 1.1% | 6.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% |
| ROE % | - | - | - | - | - | - | - | - | - | - | 0.8% | 0.5% | 0.2% | -174.9% | -1.2% |
| ROCE % | 24.3% | 26.9% | 21.4% | 13.5% | 15.5% | 11.9% | 10.5% | 1.5% | 7.3% | 2.1% | 2.2% | 0.7% | 0.5% | 0.6% | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Long Path Partners LP | 7.34% | 405.58K | $41.38M |
| 2 | Blackrock Inc. | 7.13% | 393.85K | $40.18M |
| 3 | Boston Partners | 4.86% | 268.71K | $27.41M |
| 4 | Select Equity Group LP | 4.27% | 235.88K | $24.06M |
| 5 | Vanguard Capital Management LLC | 4.21% | 232.64K | $23.73M |
| 6 | Ranger Investment Management, L.p. | 3.67% | 202.90K | $20.70M |
| 7 | AQR Capital Management, LLC | 3.09% | 170.56K | $17.40M |
| 8 | Morgan Stanley | 2.93% | 162.12K | $16.54M |
| 9 | Royce & Associates LP | 2.92% | 161.23K | $16.45M |
| 10 | Diamond Hill Capital Management Inc | 2.81% | 155.30K | $15.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLAB